【摘要】：目的:觀察玻璃體腔注射康柏西普治療濕性老年性黃斑變性(age-related macular degeneration,AMD)的有效性及安全性。方法:回顧性分析。經(jīng)眼科常規(guī)檢查、熒光素眼底血管造影(FFA)、相干光斷層掃描(OCT)檢查確診為濕性AMD的患者20例22眼,給予所有患眼玻璃體腔注射10mg/mL康柏西普0.5mg,每月注射1次,連續(xù)3次為初始治療,后根據(jù)病情需要決定是否重復(fù)治療。每月隨訪1次,隨訪觀察≥6mo。對(duì)比分析治療前后患眼最佳矯正視力(BCVA)、中心視網(wǎng)膜厚度(CRT)及黃斑區(qū)脈絡(luò)膜新生血管(CNV)病灶滲漏變化情況。結(jié)果:治療后1、3、6mo患眼平均BCVA(LogM RA)均較治療前提高,差異具有統(tǒng)計(jì)學(xué)意義(P0.01)。治療后1、3、6mo患眼平均CRT均較治療前降低,差異具有統(tǒng)計(jì)學(xué)意義(P0.01)。末次隨訪時(shí),FFA檢查,黃斑區(qū)CNV病灶滲漏消失20眼(90%);滲漏減輕2眼(9%)。隨訪期間未見(jiàn)與治療相關(guān)的嚴(yán)重眼部并發(fā)癥及全身嚴(yán)重不良反應(yīng)發(fā)生。結(jié)論:臨床實(shí)際應(yīng)用玻璃體腔注射康柏西普治療濕性AMD可提高患眼視力,降低患眼CRT,抑制新生血管滲漏,無(wú)與治療相關(guān)的不良反應(yīng)發(fā)生。
[Abstract]:Objective: to observe the efficacy and safety of intravitreous injection of Compactopril in the treatment of wettable age-related macular degeneration (age-related macular degeneration,AMD). Methods: retrospective analysis. Twenty patients (22 eyes) with wet AMD diagnosed by fluorescein fundus angiography (FFA),) coherence tomography (OCT) were given intravitreous injection of 10mg/mL (0.5 mg) into the vitreous cavity of all eyes and once a month. Three consecutive times of initial treatment, and then according to the need to determine whether to repeat treatment. The patients were followed up once a month and more than 6 moths were observed. The changes of central retinal thickness (CRT) and choroidal neovascularization (CNV) in macular area before and after treatment were analyzed. Results: the average BCVA (LogM RA) of the eyes was significantly higher than that before treatment at 1: 3 and 6 mo after treatment (P0.01). The average CRT of the eyes was significantly lower than that before treatment at 1: 3 and 6 mo after treatment (P0.01). At the last follow-up, FFA showed that CNV leakage disappeared in 20 eyes (90%) and decreased in 2 eyes (9%). There were no severe ocular complications and systemic adverse reactions associated with treatment during follow-up. Conclusion: the clinical application of intravitreal injection of Compactopril in the treatment of wet AMD can improve the visual acuity of the affected eyes and reduce the inhibition of neovascularization by CRT,. There are no adverse reactions associated with the treatment.
【作者單位】： 中國(guó)陜西省寶雞市人民醫(yī)院眼科;
【分類號(hào)】：R774.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 杜濤;;治療老年眼底黃斑變性藥物康柏西普上市[J];中國(guó)現(xiàn)代醫(yī)生;2014年25期

2 黃每裕;;傳承中藥熏蒸療法的有心人[J];家庭中醫(yī)藥;2012年02期

3 朱文漓;吳娟;葉尚宇;羅榮;喬懷耀;柯尊洪;郝曉鋒;柯瀟;鄔智剛;;RP-HPLC-ELSD法測(cè)定康柏西普眼用注射液中輔料吐溫20的含量[J];藥物分析雜志;2014年06期

4 ;[J];;年期

相關(guān)重要報(bào)紙文章 前10條

1 本報(bào)記者 陳清華;康柏，，為何也調(diào)整轉(zhuǎn)型[N];中國(guó)財(cái)經(jīng)報(bào);2001年

2 本報(bào)記者 侯旭鯤;康柏的對(duì)策[N];中國(guó)財(cái)經(jīng)報(bào);2001年

3 本報(bào)記者 李佳師;康柏如何贏得競(jìng)爭(zhēng)？[N];中國(guó)電子報(bào);2001年

4 季風(fēng);康柏獨(dú)特的管理方式[N];中國(guó)機(jī)電日?qǐng)?bào);2001年

5 ;與康柏全球總裁麥克·卡普拉斯先生面對(duì)面[N];中國(guó)高新技術(shù)產(chǎn)業(yè)導(dǎo)報(bào);2001年

6 澤華;康柏推出全新品牌戰(zhàn)略[N];國(guó)際商報(bào);2000年

7 本報(bào)記者 于飛;康柏潑墨繪明天[N];計(jì)算機(jī)世界;2000年

8 本報(bào)記者 海濱;康柏“門檻”有多高[N];計(jì)算機(jī)世界;2000年

9 本報(bào)記者 李勁松;康柏渠道回天有術(shù)[N];計(jì)算機(jī)世界;2001年

10 本報(bào)記者 楊華 陽(yáng)光;康柏反擊[N];計(jì)算機(jī)世界;2001年

相關(guān)碩士學(xué)位論文 前1條

1 黃雅清;關(guān)于惠普與康柏購(gòu)并案的利弊及啟示的研究[D];對(duì)外經(jīng)濟(jì)貿(mào)易大學(xué);2002年

本文編號(hào)：2316006